Belite Bio Dirección
Dirección controles de criterios 2/4
El CEO de Belite Bio es Tom Lin, nombrado en Nov 2021, tiene una permanencia de 6.67 años. posee directamente un 1.72% de las acciones de la empresa, con un valor de $33.64M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 3 años, respectivamente.
Información clave
Tom Lin
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | 3yrs |
| Participación del CEO | 1.7% |
| Permanencia media de la dirección | 3yrs |
| Promedio de permanencia en la Junta Directiva | 3yrs |
Actualizaciones recientes de la dirección
Recent updates
We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow
Sep 26
Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?
Jul 03We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely
Mar 20An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued
Jan 10Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 31We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
May 03Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate
Oct 03Belite Bio receives approval of begin LBS-008 phase 3 trial in China
Sep 16Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.
Aug 22Belite Bio GAAP EPS of -$0.23 beats by $0.05
Aug 12Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans
Aug 01Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment
Jul 19CEO
Tom Lin (45 yo)
3yrs
Permanencia
Dr. Yu-Hsin Lin, also known as Tom, MBA MMed PhD (Med) is the founder and has served as Director of Belite Bio Inc since March 2018 and its Chairman and served as the Chief Executive Officer since November...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board of Directors & CEO | 3yrs | sin datos | 1.72% $ 33.6m | |
| CFO & Director | 4.6yrs | sin datos | 1.01% $ 19.8m | |
| Chief Scientific Officer | 3yrs | sin datos | sin datos | |
| Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board | less than a year | sin datos | sin datos |
3.0yrs
Permanencia media
45yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BLTE se considera experimentado (3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board of Directors & CEO | 6.7yrs | sin datos | 1.72% $ 33.6m | |
| CFO & Director | 3yrs | sin datos | 1.01% $ 19.8m | |
| Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Ophthalmology Clinical Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 2.6yrs | sin datos | sin datos | |
| Member of Ophthalmology Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Ophthalmology Clinical Advisory Board | no data | sin datos | sin datos | |
| Director | 3yrs | sin datos | sin datos | |
| Director | 3yrs | sin datos | sin datos | |
| Independent Director | 2.6yrs | sin datos | sin datos | |
| Independent Director | 2.6yrs | sin datos | sin datos | |
| Member of Ophthalmology Clinical Advisory Board | no data | sin datos | sin datos |
3.0yrs
Permanencia media
45yo
Promedio de edad
Junta con experiencia: La junta directiva de BLTE se considera experimentada (3 años de antigüedad promedio).